Analyst firms · BofA Securities · ERAS
BofA Securities ERAS price target and rating history
Erasca Inc. (ERAS) · Health Care
BofA Securities rates Erasca Inc. (ERAS) Neutral with a $16 price target, as of its latest action on Jun 4, 2026. It has published 4 rating actions on ERAS since August 2021, including 1 upgrade and 2 downgrades. Across 3 firms with a ERAS price target in the last 12 months, the median target is $16. BofA Securities's target matches it.
- Current rating
- Neutral
- Price target
- $16
- Median target, all firms
- $16
- Actions on ERAS
- 4
BofA Securities price target on ERAS
Every BofA Securities rating on ERAS
- Jun 4, 2026
- Sep 3, 2025
- Jan 5, 2024
- Aug 10, 2021
How other firms rate ERAS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BofA Securities | Neutral | $16 | Jun 4, 2026 |
| Mizuho | Outperform | $16 | Jan 27, 2026 |
| Piper Sandler | Overweight | $5 | Jan 7, 2026 |
Questions about BofA Securities and ERAS
- What is BofA Securities's price target for ERAS?
- BofA Securities's latest stated price target for Erasca Inc. (ERAS) is $16, from its action on Jun 4, 2026.
- What is BofA Securities's rating on ERAS?
- BofA Securities rates ERAS Neutral, a neutral rating, as of Jun 4, 2026.
- When did BofA Securities last change its view on ERAS?
- On Jun 4, 2026, BofA Securities upgrades to Neutral from Underperform, price target $16.
- How does BofA Securities's ERAS target compare with other analysts?
- Across 3 firms with a ERAS price target in the last 12 months, the median target is $16. BofA Securities's target matches it.
More ERAS rating histories
All BofA Securities ratingsERAS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.